KNB Stock Overview
Kanabo Group Plc se dedica al desarrollo y la distribución de soluciones derivadas del cannabis para productos médicos y de bienestar.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Kanabo Group Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.018 |
| 52 Week High | UK£0.035 |
| 52 Week Low | UK£0.011 |
| Beta | 3.2 |
| 1 Month Change | 9.09% |
| 3 Month Change | -12.20% |
| 1 Year Change | -37.39% |
| 3 Year Change | -92.80% |
| 5 Year Change | n/a |
| Change since IPO | -95.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| KNB | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 2.9% | -1.8% | -0.5% |
| 1Y | -37.4% | -4.7% | 0.4% |
Rentabilidad frente al sector: KNB obtuvo unos resultados inferiores a los del sector UK Pharmaceuticals , que el año pasado arrojó un rendimiento del -5.5%.
Rentabilidad vs. Mercado: KNB obtuvo unos resultados inferiores a los del mercado UK, que fue del -5.3% el año pasado.
Price Volatility
| KNB volatility | |
|---|---|
| KNB Average Weekly Movement | 12.1% |
| Pharmaceuticals Industry Average Movement | 8.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Precio estable de las acciones: KNBha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: KNB(12%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de los valores de UK.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 23 | Avihu Tamir | https://www.kanabogroup.com |
Kanabo Group Plc se dedica al desarrollo y la distribución de soluciones derivadas del cannabis para productos médicos y de bienestar. Opera a través de los segmentos de Atención Primaria y Atención Secundaria. La empresa ofrece productos sin tetrahidrocannabinol para consumidores de cannabidiol.
Kanabo Group Plc Fundamentals Summary
| KNB fundamental statistics | |
|---|---|
| Market cap | UK£11.38m |
| Earnings (TTM) | -UK£4.65m |
| Revenue (TTM) | UK£813.00k |
14.0x
P/S Ratio-2.5x
P/E RatioIs KNB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KNB income statement (TTM) | |
|---|---|
| Revenue | UK£813.00k |
| Cost of Revenue | UK£625.00k |
| Gross Profit | UK£188.00k |
| Other Expenses | UK£4.83m |
| Earnings | -UK£4.65m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0073 |
| Gross Margin | 23.12% |
| Net Profit Margin | -571.46% |
| Debt/Equity Ratio | 4.3% |
How did KNB perform over the long term?
See historical performance and comparison